Show simple item record

dc.contributor.authorRibeiro, G
dc.contributor.authorPalmer, Michael K
dc.date.accessioned2014-12-09T12:09:34Z
dc.date.available2014-12-09T12:09:34Z
dc.date.issued1983-03-12
dc.identifier.citationAdjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. 1983, 286 (6368):827-30 Br Med J (Clin Res Ed)en
dc.identifier.issn0267-0623
dc.identifier.pmid6403101
dc.identifier.urihttp://hdl.handle.net/10541/336982
dc.description.abstractA large controlled clinical trial with the admission of 1005 patients was carried out using tamoxifen as adjuvant treatment for women with operable carcinoma of the breast. Results were analysed for the first 906 evaluable patients randomised up to December 1981. After mastectomy premenopausal women were randomised to receive either an irradiation menopause or tamoxifen 20 mg daily for one year. Postmenopausal women were randomised to receive either tamoxifen 20 mg daily for one year or no systemic treatment (controls). Analysis at five years suggested that for premenopausal women there was no significant difference between an irradiation menopause and tamoxifen in terms of survival, local recurrence, or distant metastases. Tamoxifen had no appreciable side effects. For postmenopausal women there was a trend in favour of tamoxifen with regard to survival and incidence of distant metastases, and the difference became statistically significant for those patients with four or more positive axillary nodes. If long term results of these studies show only an improved quality of remaining life with tamoxifen, then this drug could be an important contribution to adjuvant treatment.
dc.language.isoenen
dc.rightsArchived with thanks to British medical journal (Clinical research ed.)en
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshBone Neoplasms
dc.subject.meshBreast Neoplasms
dc.subject.meshClinical Trials as Topic
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMastectomy
dc.subject.meshMenopause
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshOvary
dc.subject.meshRandom Allocation
dc.subject.meshTamoxifen
dc.titleAdjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital and Holt Radium Institute, Withington, Manchester M20 9BXen
dc.identifier.journalBritish Medical Journalen
html.description.abstractA large controlled clinical trial with the admission of 1005 patients was carried out using tamoxifen as adjuvant treatment for women with operable carcinoma of the breast. Results were analysed for the first 906 evaluable patients randomised up to December 1981. After mastectomy premenopausal women were randomised to receive either an irradiation menopause or tamoxifen 20 mg daily for one year. Postmenopausal women were randomised to receive either tamoxifen 20 mg daily for one year or no systemic treatment (controls). Analysis at five years suggested that for premenopausal women there was no significant difference between an irradiation menopause and tamoxifen in terms of survival, local recurrence, or distant metastases. Tamoxifen had no appreciable side effects. For postmenopausal women there was a trend in favour of tamoxifen with regard to survival and incidence of distant metastases, and the difference became statistically significant for those patients with four or more positive axillary nodes. If long term results of these studies show only an improved quality of remaining life with tamoxifen, then this drug could be an important contribution to adjuvant treatment.


This item appears in the following Collection(s)

Show simple item record